Recent Updates
Recently added Catalysts

SAM-315

Phase 1

Alzheimer Disease | Small molecule | Neurology |Pfizer, Inc.|Last Updated: Dec 5, 2007

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLED
Total Trials2
Total Enrollment88
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00480467Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315 in Healthy Japanese MalesPHASE1 COMPLETED 32Sep 1, 2006Aug 1, 2007Dec 5, 20071 Japan
NCT00479440Study Evaluating the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-315 in Healthy AdultsPHASE1 COMPLETED 56Aug 1, 2006Mar 1, 2007Dec 5, 2007 -
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Safety and tolerability
Secondary Endpoints
Pharmacokinetics and pharmacodynamics
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelSINGLE_GROUP
PurposeTREATMENT
Interventions
NameTypeDescription
SAM-315DRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range20 Years — 45 Years
SexMALE
Healthy VolunteersYes
Study Sites1

Inclusion criteria: * Men aged 20 to 45 years (inclusive) at the time of getting informed consent. * Body mass index (BMI) in the range of 18.5 to 25.0 kg/m2 and body weight≥50 kg (BMI = \[weight (kg)\]/\[height (m)\]2). * Healthy as determined by the investigator on the basis of medical history, p...

Countries:Japan
Unlock Eligibility Criteria